Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viracta Therapeutics Inc.

www.viracta.com

Latest From Viracta Therapeutics Inc.

Venture Funding Deals: Relay Closes Out 2018 With $400m Series C

2018 was a banner year for venture funding, and Relay's December Series C was only the third largest VC round of the year. Other year-end financings include Millendo, Erasca, Aristea and more... 

Deals Financing

Asia Deal Watch: Takeda, Eisai Team With Non-Profit On Review Of Novel Targets For Antibiotics

The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.

Asia Pacific Deals

Sickle cell therapies: GlycoMimetics and others target underlying causes

The standard of care in sickle cell anemia is treatment of pain during vaso-occlusive crisis (VOC) that occurs when sickled cells adhere and block the flow of blood and oxygen, but there are a handful of therapies in development that seek to transform treatment of the disease by interrupting blockages or preventing sickled cells.

Cardiovascular Cancer

HemaQuest expands Phase II remit for HQK-1001 in sickle cell disease

HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.

Cardiovascular Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • HemaQuest Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Viracta Therapeutics Inc.
  • Senior Management
  • Ivor Royston, MD, CEO
    Dan Chevallard, CFO
    Marshelle Smith Warren, MD, CMO
    David Slack, CBO
    Robert McRae, VP, R&D & Operations
  • Contact Info
  • Viracta Therapeutics Inc.
    Phone: (858) 400-8470
    2533 S. Coast Hwy 101
    Ste. 210
    Cardiff, CA 92007
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register